Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
- Conditions
- Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8
- Interventions
- Other: Decision Aid iCanDecide - ESE websiteOther: Decision Aid iCanDecide - S websiteProcedure: Therapeutic Conventional SurgeryOther: TrainingOther: Media InterventionOther: InterviewOther: Best PracticeOther: Survey AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 543
- Registration Number
- NCT04549571
- Locations
- 🇺🇸
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States
🇺🇸SSM Health Good Samaritan, Mount Vernon, Illinois, United States
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
- Conditions
- Recurrent Lung AdenocarcinomaStage IV Lung Cancer AJCC v8Metastatic Lung AdenocarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IVB Lung Cancer AJCC v8Recurrent Lung Non-Small Cell CarcinomaStage IVA Lung Cancer AJCC v8
- Interventions
- Other: Comprehensive Geriatric AssessmentOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-08-31
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 101
- Registration Number
- NCT04533451
- Locations
- 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸ProHealth Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- Conditions
- Anatomic Stage IA Breast Cancer AJCC V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage IIA Breast Cancer AJCC V8Anatomic Stage IIB Breast Cancer AJCC V8Anatomic Stage III Breast Cancer AJCC V8Anatomic Stage IIIA Breast Cancer AJCC V8Anatomic Stage IIIB Breast Cancer AJCC V8Anatomic Stage IIIC Breast Cancer AJCC V8HER2 Positive Breast CarcinomaInvasive Breast Carcinoma
- Interventions
- Drug: Placebo AdministrationOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1031
- Registration Number
- NCT04457596
- Locations
- 🇺🇸
Hematology Oncology Associates of Central New York-Onondaga Hill, Syracuse, New York, United States
🇺🇸Upstate Cancer Center at Verona, Verona, New York, United States
🇺🇸Good Samaritan University Hospital, West Islip, New York, United States
A Clinical Study Evaluating the Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant to Testosterone-Deprivation Therapy
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC V8Stage IVA Prostate Cancer AJCC V8Stage IVB Prostate Cancer AJCC V8
- Interventions
- Drug: PlaceboOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT04455750
- Locations
- 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8HER2 Negative Breast CarcinomaHormone Receptor Positive Breast CarcinomaPrognostic Stage II Breast Cancer AJCC v8
- Interventions
- Other: Educational InterventionOther: Best PracticeBehavioral: Motivational InterviewingOther: Text Message-based Navigation InterventionOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1180
- Registration Number
- NCT04379570
- Locations
- 🇺🇸
Walter Knox Memorial Hospital, Emmett, Idaho, United States
🇺🇸Idaho Urologic Institute-Meridian, Meridian, Idaho, United States
🇺🇸Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho, United States
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
- Conditions
- Pancreatic Adenosquamous CarcinomaResectable Pancreatic AdenocarcinomaPancreatic Cancer
- Interventions
- Procedure: ResectionOther: Questionnaire Administration
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 352
- Registration Number
- NCT04340141
- Locations
- 🇺🇸
ECU Health Oncology Kinston, Kinston, North Carolina, United States
🇺🇸Duke Cancer Center Raleigh, Raleigh, North Carolina, United States
🇺🇸MetroHealth Medical Center, Cleveland, Ohio, United States
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
- Conditions
- Malignancy
- Interventions
- Procedure: Biospecimen CollectionOther: Medical Chart Review
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 240
- Registration Number
- NCT04242095
- Locations
- 🇺🇸
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive, Iowa, United States
🇺🇸MercyOne Genesis Davenport Medical Center, Davenport, Iowa, United States
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients with Stage II-III Colorectal Cancer
- Conditions
- Stage II Colorectal Cancer AJCC V8Stage III Colorectal Cancer AJCC V8
- Interventions
- Other: Quality-of-Life AssessmentOther: PlaceboOther: Questionnaire Administration
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 220
- Registration Number
- NCT04137107
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease
- Conditions
- Metastatic Malignant Neoplasm in the Brain
- Interventions
- Radiation: Fractionated Stereotactic RadiosurgeryRadiation: Single Fraction Stereotactic RadiosurgeryProcedure: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 242
- Registration Number
- NCT04114981
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Dietary Supplement: CholecalciferolOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 455
- Registration Number
- NCT04094688
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States